DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Up 7.0 %

NASDAQ DRRX opened at $0.83 on Tuesday. The stock’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.24. DURECT has a 52 week low of $0.62 and a 52 week high of $1.88. The company has a market capitalization of $25.61 million, a P/E ratio of -1.35 and a beta of 0.94.

Institutional Investors Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Richmond Brothers Inc. raised its position in shares of DURECT Co. (NASDAQ:DRRX) by 39.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,072,014 shares of the specialty pharmaceutical company’s stock after purchasing an additional 303,670 shares during the period. DURECT comprises 2.7% of Richmond Brothers Inc.’s portfolio, making the stock its 7th biggest position. Richmond Brothers Inc. owned 3.45% of DURECT worth $1,383,000 at the end of the most recent reporting period. 28.03% of the stock is owned by hedge funds and other institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.